Next Article in Journal
Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma
Next Article in Special Issue
Racial Disparities in Breast Cancer Treatments and Adverse Events in the SEER-Medicare Data
Previous Article in Journal
Impact of Bevacizumab on Visual Function, Tumor Size, and Toxicity in Pediatric Progressive Optic Pathway Glioma: A Retrospective Nationwide Multicentre Study
Previous Article in Special Issue
Safety of Anti-Angiogenic Drugs in Pediatric Patients with Solid Tumors: A Systematic Review and Meta-Analysis
 
 
Article

Article Versions Notes

Cancers 2022, 14(24), 6083; https://doi.org/10.3390/cancers14246083
Action Date Notes Link
article xml file uploaded 10 December 2022 15:19 CET Original file -
article xml uploaded. 10 December 2022 15:19 CET Update -
article pdf uploaded. 10 December 2022 15:19 CET Version of Record https://www.mdpi.com/2072-6694/14/24/6083/pdf-vor
article html file updated 10 December 2022 15:20 CET Original file -
article xml file uploaded 22 December 2022 10:18 CET Update -
article xml uploaded. 22 December 2022 10:18 CET Update https://www.mdpi.com/2072-6694/14/24/6083/xml
article pdf uploaded. 22 December 2022 10:18 CET Updated version of record https://www.mdpi.com/2072-6694/14/24/6083/pdf
article html file updated 22 December 2022 10:19 CET Update -
article html file updated 1 March 2023 03:38 CET Update -
article html file updated 4 March 2023 20:47 CET Update https://www.mdpi.com/2072-6694/14/24/6083/html
Back to TopTop